Mao-Lin Yan

1.1k total citations
61 papers, 726 citations indexed

About

Mao-Lin Yan is a scholar working on Hepatology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mao-Lin Yan has authored 61 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hepatology, 30 papers in Surgery and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mao-Lin Yan's work include Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (26 papers) and Cancer Mechanisms and Therapy (11 papers). Mao-Lin Yan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (35 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (26 papers) and Cancer Mechanisms and Therapy (11 papers). Mao-Lin Yan collaborates with scholars based in China, United States and Hong Kong. Mao-Lin Yan's co-authors include Funan Qiu, Jiayi Wu, Yifeng Tian, Shi Chen, Songqiang Zhou, Jiaqiang Zhang, Jiang-Zhi Chen, Yinan Li, Jianyin Zhou and Yufeng Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Mao-Lin Yan

49 papers receiving 725 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mao-Lin Yan China 14 316 228 224 221 203 61 726
Meihai Deng China 15 238 0.8× 214 0.9× 96 0.4× 146 0.7× 299 1.5× 45 667
Takumi Irie Japan 17 271 0.9× 154 0.7× 303 1.4× 189 0.9× 191 0.9× 42 674
Nafis Shafizadeh United States 14 275 0.9× 90 0.4× 175 0.8× 299 1.4× 133 0.7× 20 625
Shoichi Dowaki Japan 13 197 0.6× 95 0.4× 345 1.5× 361 1.6× 159 0.8× 36 710
Tsung‐Hui Hu Taiwan 8 242 0.8× 107 0.5× 104 0.5× 100 0.5× 271 1.3× 12 566
Yosuke Tsuruga Japan 13 254 0.8× 62 0.3× 168 0.8× 225 1.0× 111 0.5× 43 516
Eleni Vrettou Greece 15 145 0.5× 72 0.3× 304 1.4× 93 0.4× 147 0.7× 33 562
Poh Seng Tan Singapore 12 259 0.8× 124 0.5× 67 0.3× 128 0.6× 156 0.8× 26 541
Yongliang Sun China 13 139 0.4× 108 0.5× 121 0.5× 211 1.0× 123 0.6× 34 473
K Shirabe Japan 12 405 1.3× 92 0.4× 103 0.5× 226 1.0× 59 0.3× 34 569

Countries citing papers authored by Mao-Lin Yan

Since Specialization
Citations

This map shows the geographic impact of Mao-Lin Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mao-Lin Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mao-Lin Yan more than expected).

Fields of papers citing papers by Mao-Lin Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mao-Lin Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mao-Lin Yan. The network helps show where Mao-Lin Yan may publish in the future.

Co-authorship network of co-authors of Mao-Lin Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Mao-Lin Yan. A scholar is included among the top collaborators of Mao-Lin Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mao-Lin Yan. Mao-Lin Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Kang, Hongming Yu, Yuqiang Cheng, et al.. (2025). Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial. Signal Transduction and Targeted Therapy. 10(1). 328–328.
2.
3.
Wu, Jiayi, Junyi Wu, Zhibo Zhang, et al.. (2024). Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery. Liver Cancer. 13(5). 498–508. 7 indexed citations
4.
Wu, Junyi, Zhibo Zhang, Shuangjia Wang, et al.. (2024). Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study. Journal of Hepatocellular Carcinoma. Volume 11. 1777–1787.
5.
6.
Wu, Jiayi, De-Yi Liu, Han Li, et al.. (2023). Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?. Journal of Hepatocellular Carcinoma. Volume 10. 2161–2171. 6 indexed citations
7.
8.
Wu, Jiayi, Jinhai Li, De-Yi Liu, et al.. (2023). Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma. Volume 10. 1799–1811. 16 indexed citations
9.
Wu, Jiayi, Junyi Wu, Yinan Li, et al.. (2023). The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors. Hepatology International. 18(2). 651–660. 10 indexed citations
10.
11.
Ruan, Dan‐dan, et al.. (2021). Mutational Analysis of a Familial Adenomatous Polyposis Pedigree with Bile Duct Polyp Phenotype. Canadian Journal of Gastroenterology and Hepatology. 2021(1). 6610434–6610434. 2 indexed citations
12.
Bai, Yannan, Jiayi Wu, Shi Chen, et al.. (2021). A Prognostic Scoring System for Predicting Overall Survival of Patients with the TNM 8th Edition Stage I and II Hepatocellular Carcinoma After Surgery: A Population-Based Study. Cancer Management and Research. Volume 13. 2131–2142. 3 indexed citations
13.
Wu, Jiayi, Zhenyu Yin, Yannan Bai, et al.. (2021). Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. SHILAP Revista de lepidopterología. Volume 8. 1233–1240. 100 indexed citations
14.
15.
16.
Wang, Xicheng, Xining Wang, Yunxiuxiu Xu, et al.. (2020). Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation. Cancer Cell International. 20(1). 91–91. 20 indexed citations
17.
Huang, Long, Yifeng Tian, Jiayi Wu, et al.. (2020). The effectiveness, risks and improvement of laparoscopic pancreaticoduodenectomy during the learning curve: a propensity score-matched analysis. Gland Surgery. 9(4). 985–999. 9 indexed citations
18.
Chen, Shi, Jiang-Zhi Chen, Jiaqiang Zhang, et al.. (2019). Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8. Cancer Letters. 446. 49–61. 80 indexed citations
19.
Yan, Mao-Lin. (2015). Adenomas of the common bile duct in familial adenomatous polyposis. World Journal of Gastroenterology. 21(10). 3150–3150. 9 indexed citations
20.
Chen, Yongbing, Mao-Lin Yan, Lixin Liu, et al.. (2007). Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1. Chinese Medical Journal. 120(8). 703–707. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meihai Deng Breakdown of academic impact, for papers by Takumi Irie Breakdown of academic impact, for papers by Nafis Shafizadeh Breakdown of academic impact, for papers by Shoichi Dowaki Breakdown of academic impact, for papers by Tsung‐Hui Hu Breakdown of academic impact, for papers by Yosuke Tsuruga Breakdown of academic impact, for papers by Eleni Vrettou Breakdown of academic impact, for papers by Poh Seng Tan Breakdown of academic impact, for papers by Yongliang Sun Breakdown of academic impact, for papers by K Shirabe
Rankless by CCL
2026